Study of Lanreotide in Non Metastatic Castration-resistant Prostate Cancer Patients

The aim of the study is to compare in an exploratory fashion the efficacy on progression-free survival of lanreotide in addition to non steroidal anti androgens and LHRH-a in non metastatic castrate resistant prostate cancer patients.

En rapport Clinical Trials